Multi-strain Probiotic Effects on Self-Reported Constipation
NCT ID: NCT07275866
Last Updated: 2025-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
20 participants
INTERVENTIONAL
2025-10-03
2026-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Pre, pro- and synbiotics have emerged as one alternative treatment, and a growing body of evidence now supports their use in a proportion of individuals with mild constipation. However, it is currently not possible to predict which individuals may benefit. A better understanding of an individuals' symptoms and underlying pathophysiology may allow for more targeted treatment.
The multistrain live bacterial food product (probiotic) being tested contains billions of live and active bacteria that has been shown to improve symptoms in the irritable bowel syndrome (IBS: which is 'constipation-predominant' in many). Notably, improvements ('completely resolved' or 'some positive difference') in bowel habit satisfaction, abdominal pain, bloating and urgency, as well as on quality of life have been shown after 4 or more weeks of this probiotc.
This study aims to have 20 participants with self-reported constipation to assess improvements in constipation symptoms, quality of life and measures of gut function.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Multi-strain Liquid Probiotic
70ml of a multi-strain liquid probiotic taken daily for 28-35 days
Multi-strain probiotics
28-35 days of 70 ml Symprove once daily, to be taken on an empty stomach upon waking. 10 minutes should be taken between ingestion of Symprove before eating and drinking.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Multi-strain probiotics
28-35 days of 70 ml Symprove once daily, to be taken on an empty stomach upon waking. 10 minutes should be taken between ingestion of Symprove before eating and drinking.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Participant has Cleveland Clinic constipation score (CCCS) of 9-16 at screening call
3. Participant is willing to discontinue all other therapies for constipation and undergo washout where applicable.
4. Participant is a male or non-pregnant female and is 18-70 years of age
5. If WOCBP participant is willing to adhere to one of the following methods of contraception:
i) Hormonal contraception e.g. the 'pill' or an implant ii) Intrauterine device (IUD) iii) Intrauterine hormone-releasing system (IUS) vi) Sexual abstinence (if it is in line with participants' preferred and usual lifestyle).
or has had a: v) Hysterectomy or has a: vi) Vasectomised partner
6. Participant can communicate well with the Investigator and to comply with the requirements for the entire study.
7. Participant has capacity to understand written English.
8. Participant has a body mass index (BMI) of 18.5 - 39.9kg/m2 (bounds included).
9. Participant agrees to follow all pre-test preparation for the ATMO capsule transit study.
Exclusion Criteria
2. Participants who are planning to significantly change their diet (e.g. weight loss program, becoming vegetarian) during the study period.
3. Participant has had diarrhoea within 7 weeks of screening period.
4. Prior abdominal surgery involving resection of the small or large bowel.
5. Prior bariatric surgery involving resection of the stomach or by-pass procedures.
6. Type 1 diabetes mellitus.
7. Known organic or structural GI disease including:
* Coeliac disease
* Inflammatory bowel disease
* Diverticulitis
* Small bowel strictures
8. Irritable bowel syndrome where the predominant symptom is pain (assessed via screening questions).
9. Oropharyngeal dysphagia or difficulty swallowing capsules.
10. Any other medical condition that the investigator deems may confound results or affect participants' safety in the study.
11. Any use of prohibited medication that the participant cannot complete appropriate washout for.
12. Insufficient knowledge of English to complete the daily bowel diary.
13. Allergy to any component of the supplement, motility bar, lactulose or Zoe blue cookie.
14. Participant is involved in this study as an investigator, sub-Investigator, study coordinator, other study staff, or Sponsor member.
15. Previous use of the probiotic Symprove.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dr Anthony Hobson
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr Anthony Hobson
Clinical Director and Senior Clinical GI Scientist
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Functional Gut Clinic
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Fay Rendall
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FGC-25-02
Identifier Type: -
Identifier Source: org_study_id